Effects of Ro 40-5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: comparison with verapamil.

Journal of Cardiovascular Pharmacology
J P ClozelW Osterrieder

Abstract

Ro 40-5967 is a structurally novel calcium antagonist that binds to the verapamil binding site but has very weak negative inotropic effects compared to verapamil. The goals of the present study were to assess the effects of Ro 40-5967 on myocardial function during ischemia, and to compare them to those of verapamil. For this purpose, in anesthetized dogs where the circumflex coronary artery was cannulated and perfused at controlled pressure, myocardial function was measured using piezo electric crystals implanted into the endocardium. Myocardial distribution of coronary blood flow was assessed using radioactive microspheres. Ischemia was produced by lowering perfusion pressure from 100 to 15 mm Hg in steps. During ischemia, Ro 40-5967 partially prevented the decrease of segmental shortening (p less than 0.01) and increased coronary flow, especially in the endocardium (p less than 0.01). In contrast, verapamil did not improve myocardial function during ischemia. The protective effect of Ro 40-5967 could be partially explained by the decrease of arterial pressure and heart rate induced by Ro 40-5967. However, Ro 40-5967 injected directly inside the coronary artery did not induce systemic effects, but still had protective effects ...Continue Reading

Citations

Sep 2, 1998·Journal of Clinical Pharmacology·S P Glasser
Oct 8, 1999·European Journal of Drug Metabolism and Pharmacokinetics·J PetersR Bullingham
Jul 21, 1995·Journal of Chromatography. B, Biomedical Applications·A Skerjanec, Y K Tam
Aug 1, 1996·Journal of the American College of Cardiology·A M Katz
Dec 31, 1997·The American Journal of Cardiology·B M Massie
Jan 1, 1997·Clinical Therapeutics·P E Pool
Nov 30, 2002·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Petra De PaoliAlessandro Mugelli
Apr 28, 2001·Journal of Pharmacological and Toxicological Methods·R Tabrizchi, M K Pugsley
Nov 7, 1998·British Journal of Pharmacology·S AczélS Hering
Apr 16, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Peter H BuiOliver Hankinson
Jan 28, 2003·Circulation Journal : Official Journal of the Japanese Circulation Society·Kenji HaradaSusumu Ito
Feb 25, 2014·Pflügers Archiv : European journal of physiology·Bernd Nilius, Emilio Carbone
Jan 1, 1997·Clinical Therapeutics·B Pitt
May 1, 1997·Expert Opinion on Investigational Drugs·S I Ertel, J P Clozel
Dec 28, 2007·Bioorganic & Medicinal Chemistry Letters·Jon J HangelandWilliam R Ewing
Aug 1, 1996·Journal of Cardiovascular Pharmacology·D Karila-CohenA Berdeaux
May 1, 1996·Journal of Cardiovascular Pharmacology·E Vacher Giudicelli
May 1, 1996·Journal of Cardiovascular Pharmacology·H J MuntingaK I Lie
Jun 26, 1998·The Annals of Pharmacotherapy·S J Billups, B L Carter
Feb 23, 2000·Journal of Cardiovascular Pharmacology and Therapeutics·W H Frishman
Mar 3, 1998·Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension·J P ClozelS I Ertel
Mar 3, 1998·Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension·F R Bühler

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Related Papers

Proceedings of the National Academy of Sciences of the United States of America
Romain LyA Feltz
Pflügers Archiv : European journal of physiology
Régis C LambertNathalie Leresche
British Journal of Clinical Pharmacology
Kim L PowellTerence J O'Brien
© 2022 Meta ULC. All rights reserved